Dr. Henry Conter is solving the impossible problems in healthcare by re-imagining how all types of people can take control of their care and maximize their experience and outcomes. He is the portfolio manager of early development oncology in the pharmaceuticals Research and Early Discovery division at Hoffman La-Roche, focused on clinical trials design that reflects the needs of patients, clinicians, and their representatives. He continues as a practicing general medical oncologist/hematologist at William Osler Health System.

Prior to joining Roche, Dr. Conter has a track record for innovation and excellence in leadership as Chief of Hematology/Oncology, Medical Director of the Cancer Health System, and Executive Medical Director of Quality, Patient Safety, and Health System integration at Osler. He served as a voting member on the Ontario Steering Committee for Cancer Drugs and a member of the pan-Canadian Oncology Drug Review (pCODR) Expert Review Panel and CADTHs national Pharmacare Advisory Panel as the oncology representative. Previously he served on pCODR’s Economic Guidance Panels and Clinical Guidance Panels.

Dr. Conter completed his undergraduate degree in mechanical engineering at the University of Western Ontario in 2007. He graduated from McMaster School of Medicine in 2008. He then went to the University of Alberta where he completed his clinical residency in internal medicine in 2011, and received his MSc in health technology assessment in 2012. He completed his clinical fellowship in medical oncology at the University of Texas M.D. Anderson Cancer Center in Houston Texas, and a Masters in Finance at the University of Houston in 2013. He was an assistant professor at the University of Western Ontario in the department of Oncology prior to joining Osler.